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Pulmonary arterial hypertension is a major complication of systemic sclerosis. Although oxidative stress, intima
hyperplasia and a progressive vessel occlusion appear to be clearly involved, the fine molecular mechanisms
underpinning the onset and progression of systemic sclerosis-associated pulmonary arterial hypertension remain
largely unknown. Here we shows for the first time that an increase of NADPH-derived reactive oxygen species
production induced by sera from systemic sclerosis patients with pulmonary arterial hypertension drives collagen
type I promoter activity in primary human pulmonary artery smooth muscle cells, suggesting that antioxidant-based
therapies should be considered in the treatment of systemic sclerosis-associated vascular diseases.
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Background
Pulmonary arterial hypertension (PAH) is a serious compli-
cation associated with significant morbidity and unfavorable
outcomes in systemic sclerosis (SSc) [1]. This disease
process is characterized by proliferative and fibrotic events
involving all three layers of the blood vessel wall in the
pulmonary circulation resulting from impaired function of
endothelial and vascular smooth muscle cells (VSMCs)
[2,3]. Under homeostatic conditions, VSMCs exhibit a
contractile phenotype, which regulate blood vessel diam-
eter by virtue of stretch-sensing mechanisms. During
vascular injury, a “phenotypic switch” can occur in
response to pro-inflammatory, hypoxic and mitogenic
stimuli, conferring to VSMCs the ability to migrate into
intimal layers, differentiate, proliferate and synthesize
extracellular matrix [4]. Inadequate regulation of this
process contributes to the progressive narrowing and
obliteration of pulmonary arterioles in SSc-PAH. Oxidative* Correspondence: gpintus@uniss.it
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unless otherwise stated.stress has been previously linked to vascular dysfunction,
intimal hyperplasia and progressive vessel occlusion in SSc
[5]. It is possible that circulating pro-oxidant factors may
be involved in the pathogenesis of SSc-PAH through their
ability to induce VSMCs activation and phenotypic switch.
In order to verify this hypothesis, we investigated the
production of reactive oxygen species (ROS) and collagen
synthesis in primary human pulmonary artery smooth
muscle cells (HPASMCs) exposed to serum obtained from
SSc patients with or without PAH confirmed by right
heart catheterization (RHC) and healthy donors (HD)
(Table 1).
Methods
All SSc patients met the American College of Rheumatol-
ogy criteria or had 3 of 5 features of the CREST (Calcinosis,
Raynaud’s syndrome; Esophageal dysmotility; Sclerodactyly;
Telangiectasia) syndrome [6]. SSc subjects were indicated
as “No PAH” (n = 17) if their right ventricular systolic
pressure (RVSP) estimated by echocardiogram was ≤35
mm Hg, while they were defined as “PAH” (n = 19) if the
RVSP was >35 mm Hg and they underwent RHC showing
a mean pulmonary artery pressure (mPAP) ≥ 25 mm Hgd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient demographics and clinical characteristics
Variables No PAH (N = 17) PAH (N = 19) HD (N = 14) p value§
Age at serum sampling (years)* 53.3 ± 11.6 64.0 ± 9.4 54.1 ± 10.4 0.009
Female 15 (88) 16 (84) 15 (85) 0.727
Race
White 14 (82) 16 (84) 12 (80) 0.881
Black 3 (18) 3 (16) 3 (20)
Smoking status
Never 9 (53) 10 (53) 8 (53) 0.280
Past 6 (35) 9 (47) 5 (33)
Current 2 (12) 0 2 (13)
SSc types
Limited 11 (65) 16 (84) 0.177
Diffuse 6 (35) 3 (16)
mRSS* (range 0–51) 5.5 ± 6.1 7.3 ± 10.3 0.567
SSc duration (RP onset)*, years 14.0 ± 12.6 21.7 ± 9.4 0.008
SSc duration (1st non-RP symptom)*, years 10.5 ± 7.3 18.5 ± 9.5 0.010
RP severity score* (range 0–4) 1.6 ± 0.8 2.0 ± 1.0 0.194
Heart severity score* (range 0–4) 0.2 ± 0.7 1.2 ± 1.7 0.062
Lung severity score* (range 0–4) 1.1 ± 1.3 3.1 ± 1.3 <0.001
Hemodynamics (RHC)
mPAP* (mm Hg) NA 35.2 ± 8.1 NA
PCWP* (mm Hg) NA 11.5 ± 4.0 NA
FVC* (% predicted) 81.9 ± 22.9 73.1 ± 9.9 0.149
DLCO* (% predicted) 78.2 ± 23.0 48.7 ± 16.8 <0.001
RLD† 6 (35) 6 (32) 0.813
eRVSP* 24.0 ± 6.3 65.2 ± 19.9 <0.001
Autoantibody status
ACA 4 (24) 10 (53) 0.07
Anti-Scl-70 7 (41) 1 (5) 0.01
Anti-RNA-polymerase 3 2 (12) 0 0.124
Medication use (current)
Immunosuppressants‡ 5 (29) 5 (26) 0.836
Calcium channel blocker 10 (59) 7 (37) 0.187
Endothelin receptor antagonist 1 (6) 6 (32) 0.052
Phosphodiesterase 5 inhibitor 4 (24) 11 (58) 0.037
Prostanoid 0 0 NA
Statin 6 (35) 5 (26) 0.559
Aspirin 5 (29) 5 (26) 0.836
All values are given as number (%) unless otherwise specified.
*Mean ± SD. †The presence of RLD was defined by a FVC < 70% of predicted. ‡Use of immunosuppressants include cyclophosphamide, mycophenolate,
methotrexate, hydroxycholorquine or prednisone. §P values were determined by Fisher’s exact test or the Wilcoxon rank-sum test, as appropriate.
ACA, anticentromere antibody; DLCO, diffusion capacity of lung for carbon monoxide; eRVSP, estimated right ventricular systolic pressure by echocardiography;
FVC, forced vital capacity; HD, healthy donors; mRSS, modified Rodnan skin score; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension,
PCWP, pulmonary capillary wedge pressure, RHC, right heart catheterization, RLD, restrictive lung disease; RP, Raynaud’s phenomenon; Scl-70, topoisomerase I; SSc,
systemic sclerosis.
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Figure 1 Effect of sera on intracellular ROS levels and collagen promoter activity. (A-B) Effects of SSc sera on human pulmonary artery
smooth muscle cells (HPASMCs) intracellular ROS production. Before stimulation, sub-confluent HPASMCs were loaded with 10 μM of H2-DCFDA and
then cultured in basal medium containing 10% (V/V) of sera from scleroderma (SSc) patients with pulmonary arterial hypertension (PAH), without PAH
(No PAH) and healthy donors (HD) ††. Variations in intracellular ROS levels were kinetically determined in a 4 hour time-course experiment (Figure 1A)
and values at 2 hours (steady state) used for comparison (Figure 1B). Fluorescence data were normalized for protein content and expressed as Relative
Fluorescence Units (RFU). (D-E) Effects of SSc sera on HPASMCs collagen (COL1A1) promoter activation. Sub-confluent HPASMCs were transduced with
lentiviral particles obtained from the COL1A1-LV-tGFP and EF1α-LV-FP602 lentivectors, and then cultured in basal medium containing 10% (V/V) of
sera from PAH, no PAH and HD subjects. Variations of COL1A1 promoter activation were kinetically followed for 10 hours (Figure 1D) and
values at 8 hours (steady state) used for comparison (Figure 1E). Data are normalized for transduction efficiency by reporting the ratio of
COL1A1-LV-tGFP to EF1α-LV-FP602 Relative Fluorescence Units (RFU). (C-F) In selected experiments, HPASMCs were incubated for 1 hour with
5 μM NADPH oxidase specific inhibitor NOX2ds-tat (NOX) before treatment with SSc sera. ††Healthy donors were matched for gender, race and smoking
status. Horizontal lines indicate the median with interquartile range. Kruskall–Wallis one-way analysis of variance followed by post-hoc Dunn’s test for
multiple comparisons were used to detect differences among studied groups in Figures 1B and E. Wilcoxon matched-pairs signed rank test was used to
determine meaningful differences between pre- and post-NOX treatment pairs in Figures C and F. All statistical analysis were performed using GraphPad
Prism version 6.00 for Windows (GraphPad Software, San Diego, CA) and p-values <0.05 were considered to be statistically significant.
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mm Hg. HD (n = 14) were selected through a screening
questionnaire to rule out any underlying autoimmune or
vascular disease. Intracellular ROS levels were assessed in
HPASMCs using the oxidative stress indicator dichlorodi-
hydrofluorescein-diacetate (H2-DCFDA), while collagen
type-I (COL1A1) synthesis was investigated employing
COL1A1-LV-tGFP, a GFP-based lentiviral vector (LV)
driven by the human COL1A1 gene promoter [7,8]. A
red fluorescence protein-based LV (EF1α-LV-FP602)
was used to normalize the cell transduction efficiency.
In selected experiments, HPASMCs were pretreated
before serum exposure with a NADPH oxidase specific
inhibitor (NOX2ds-tat, formerly gp91ds-tat) [9]. SSc dis-
ease duration was calculated at the time of serum sampling
from the onset of RP or from the first non-RP symptom.
RP, heart and lung severity scores are reported as previously
defined by Medsger et al. [10]. Study subjects were enrolled
according to the protocol approved by the IRB after signing
the consent form. Healthy donors were recruited through
posted flyers and enrolled after passing a screening ques-
tionnaire aimed at excluding the presence of any underlying
vascular or autoimmune disease.
Results
SSc patients enrolled in the study were mainly middle
age, white women. Subjects with PAH were slightly older
(64.0 ± 9.4 vs 53.3 ± 11.6; p = 0.009) and had longer disease
duration (18.5 ± 9.5 vs 10.5 ± 7.3 years; p = 0.01). As
expected, they exhibited higher lung severity scores
(3.1 ± 1.3 vs 1.1 ± 1.3; p < 0.001) and a significantly
lower diffusion capacity of lung for carbon monoxide
(DLCO) (48.7 ± 16.8 vs 78.2 ± 23.0; p < 0.001) with
comparable forced vital capacity (FVC), indicative of
the underlying pulmonary vascular disease. The use of
vasodilators (i.e. endothelin receptor antagonists and
phosphodiesterase 5 inhibitors) was significantly higher in
PAH patients. Intracellular ROS levels were kinetically
determined in a 4-hour time-course (Figure 1A) and
values at 2 hours (steady state) were used for comparison
(Figure 1B). Sera from SSc-PAH patients significantly
increased intracellular ROS levels in HPASMCs with
median (interquartile range) of 213 (158) compared to
subjects without PAH [141 (48); p = 0.027] and HD
[130 (52); p = 0.002]. NOX2ds-tat effectively reduced
induction of ROS by PAH-SSc sera (p = 0.009), implicating
NADPH oxidase in this process (Figure 1C). Exposure of
HPASMCs to SSc-PAH sera also resulted in progressive
time-related increase of the COL1A1 promoter activity
(Figure 1D) with values at 8 hours (steady state) signifi-
cantly higher in cells exposed to PAH [2.375 (1.597)]
compared to no-PAH [1.825 (0.612); p = 0.028] and HD
[1.844 (0.265); p = 0.007] sera (Figure 1E). Similarly to
ROS production, also this effect was inhibited byNOX2ds-tat pretreatment (p = 0.005) (Figure 1F), suggest-
ing that phenotypic switch and collagen synthesis activation
in HPASMCs may be driven by SSc-related PAH sera
through NADPH-oxidase dependent ROS generation.
Conclusion
This pilot study provides new evidence supporting the
possibility that vascular disease and in particular PAH may
be driven or maintained in SSc patients by pro-oxidant
circulating factors acting, at least in part, through the
activation of collagen synthesis in VSMCs. While more
studies are needed to identify with precision these media-
tors and to define the molecular basis of their effect, our
data provide further rationale for considering anti-oxidant
therapies in the treatment or prevention of SSc-related
pulmonary vascular disease.
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